RWE Patient Advisory Counsil, Walgreens Clinical Trial, United States
Early CKM (Cardiorenal-Metabolic) Syndrome often unfolds quietly, presenting subtle clues that slip past routine evaluations. Patients may exhibit mild metabolic changes or borderline renal parameters long before overt cardiovascular disease emerges. Unfortunately, these early signs are frequently dismissed as isolated findings rather than interconnected pathophysiological markers. Recognizing this silent convergence early can transform outcomes, shifting care from reactive management to proactive prevention.
RWE Patient Advisory Counsil, Walgreens Clinical Trial, United States
Dr. Patrick O. Gee is a distinguished Healthcare Consultant, Patient Advocate, and faith leader with over two decades of multidisciplinary experience spanning healthcare consulting, patient-centered research, and community engagement. As Founder of P Gee Consulting, LLC and iAdvocate, Inc., he leverages his personal journey with Chronic Kidney Disease (CKD) to champion health equity, patient empowerment, and inclusive research across diabetes, cardiovascular, and renal health. He currently serves on the RWE Patient Advisory Council at Walgreens Clinical Trials, Executive Advisory Committee at Bayer, and as an Ambassador for the Patient-Centered Outcomes Research Institute (PCORI), offering strategic insights on patient engagement and health justice. Dr. Gee’s extensive consulting experience includes collaborations with ProKidney and Project Tech, focusing on patient experience, research equity, and healthcare access. In addition to his healthcare leadership, Dr. Gee is an Ordained Elder at Mountain Movers Ministry, Virginia, where he provides pastoral care and community outreach for underserved populations. A compelling speaker and advocate, he integrates his academic background—Ph.D. in Justice, Law, & Criminology—with his lived experience to inspire transformative change in patient care systems and chronic disease management.
Copy Link